Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.18 USD
Change Today +0.015 / 9.38%
Volume 67.0K
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

geovax labs inc (GOVX) Snapshot

Open
$0.17
Previous Close
$0.16
Day High
$0.19
Day Low
$0.17
52 Week High
10/14/14 - $0.51
52 Week Low
12/18/14 - $0.13
Market Cap
5.6M
Average Volume 10 Days
44.0K
EPS TTM
$-0.10
Shares Outstanding
32.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GEOVAX LABS INC (GOVX)

Related News

No related news articles were found.

geovax labs inc (GOVX) Related Businessweek News

No Related Businessweek News Found

geovax labs inc (GOVX) Details

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines against infectious diseases using its novel vaccine platform. The company focuses on developing vaccines against Ebola and Marburg viruses, and human immunodeficiency virus (HIV). Its vaccines under development include GOVX-B11 and GOVX-B21 vaccines that are in Phase 2a clinical trials to treat clade B subtype of HIV virus; and in preclinical research to treat clade C subtype of HIV virus. The company was founded in 2001 and is based in Smyrna, Georgia.

5 Employees
Last Reported Date: 04/9/15
Founded in 2001

geovax labs inc (GOVX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $174.2K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.6K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $214.6K
Compensation as of Fiscal Year 2014.

geovax labs inc (GOVX) Key Developments

GeoVax Labs, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Approves Amendment of Certificate Incorporation

GeoVax Labs, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported grant revenue of $103,000 against $157,000 a year ago. Loss from operations was $702 against $617 a year ago. Net loss was $700,000 or $0.02 per share against $616,000 or $0.02 per share a year ago. The company approved amendment of certificate incorporation to increase authorized shares of common stock from 75 million to 150 million, at the annual meeting of the stockholders held on May 12, 2015.

GeoVax Labs and National Institute of Allergy and Infectious Diseases to Develop Vaccines Against Ebola and Marburg Viruses

GeoVax Labs has signed a research collaboration agreement with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop its vaccines against Ebola and Marburg viruses. The deal has been established to accelerate the development of vaccines against filoviruses, the family of hemorrhagic viruses containing Ebola and Marburg. GeoVax is involved in developing both single-strain and multi-strain vaccines against Ebola and Marburg, a haemorrhagic virus similar to Ebola. GeoVax has partnered extensively with NIAID in the development of modified vaccinia Ankara (MVA) vaccines against HIV and its MVA-vectored HIV vaccines that also express non-infectious VLPs have been constructed in NIAID-developed vectors. As part of the deal, NIAID will provide materials, reagents and scientific advice for vaccine construction. It will also collaborate on the analysis of the recombinant MVA expression and stability, data analysis, and interpretation of these studies. GeoVax will involve constructing and characterising MVA-Ebola and MVA-Marburg recombinants in-vitro and prepare MVA Ebola and Marburg vaccines for animal studies. NIAID will then involve conducting animal protection studies in guinea pigs, hamsters, and non-human primates if appropriate.

GeoVax Labs, Inc. Proposes Amendment to Certificate of Incorporation

GeoVax Labs, Inc. proposed amendment to certificate of incorporation to increase authorized shares of common stock, $0.001 par value, from 75,000,000 to 150,000,000, to be considered for approval at the AGM to be held on May 12, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GOVX:US $0.18 USD +0.015

GOVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr336.50 DKK +3.00
CSL Ltd A$93.50 AUD +0.90
Emergent Biosolutions Inc $31.86 USD +0.11
Green Cross Corp/South Korea 205,500 KRW +11,500
Solvay SA €126.00 EUR -2.20
View Industry Companies
 

Industry Analysis

GOVX

Industry Average

Valuation GOVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GEOVAX LABS INC, please visit www.geovax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.